Please use this identifier to cite or link to this item: https://doi.org/10.1371/journal.pone.0056061
Title: Antigenicity and Immunogenicity of Plasmodium vivax Merozoite Surface Protein-3
Authors: Bitencourt A.R.
Vicentin E.C.
Jimenez M.C.
Ricci R.
Leite J.A.
Costa F.T.
Ferreira L.C.
Russell B. 
Nosten F.
Rénia L. 
Galinski M.R.
Barnwell J.W.
Rodrigues M.M.
Soares I.S.
Keywords: aluminum potassium sulfate
CpG oligodeoxynucleotide
flagellin
Freund adjuvant
immunoglobulin G antibody
malaria vaccine
merozoite surface protein 3
merozoite surface protein 3 alpha
merozoite surface protein 3 beta
recombinant protein
unclassified drug
animal experiment
antibody titer
antigenicity
article
Brazil
carboxy terminal sequence
controlled study
enzyme linked immunosorbent assay
erythrocyte
female
human
humoral immunity
immunization
immunofluorescence
immunogenicity
major clinical study
mouse
nonhuman
Plasmodium vivax
Plasmodium vivax malaria
protein expression
Animals
Antibody Formation
Antigens, Protozoan
Humans
Immunoglobulin G
Malaria Vaccines
Malaria, Vivax
Mice
Mice, Inbred BALB C
Mice, Inbred C57BL
Plasmodium vivax
Protozoan Proteins
Recombinant Proteins
Issue Date: 2013
Publisher: Public Library of Science
Citation: Bitencourt A.R., Vicentin E.C., Jimenez M.C., Ricci R., Leite J.A., Costa F.T., Ferreira L.C., Russell B., Nosten F., Rénia L., Galinski M.R., Barnwell J.W., Rodrigues M.M., Soares I.S. (2013). Antigenicity and Immunogenicity of Plasmodium vivax Merozoite Surface Protein-3. PLoS ONE 8 (2) : e56061. ScholarBank@NUS Repository. https://doi.org/10.1371/journal.pone.0056061
Abstract: A recent clinical trial in African children demonstrated the potential utility of merozoite surface protein (MSP)-3 as a vaccine against Plasmodium falciparum malaria. The present study evaluated the use of Plasmodium vivax MSP-3 (PvMSP-3) as a target antigen in vaccine formulations against malaria caused by P. vivax. Recombinant proteins representing MSP-3? and MSP-3? of P. vivax were expressed as soluble histidine-tagged bacterial fusions. Antigenicity during natural infection was evaluated by detecting specific antibodies using sera from individuals living in endemic areas of Brazil. A large proportion of infected individuals presented IgG antibodies to PvMSP-3? (68.2%) and at least 1 recombinant protein representing PvMSP-3? (79.1%). In spite of the large responder frequency, reactivity to both antigens was significantly lower than was observed for the immunodominant epitope present on the 19-kDa C-terminal region of PvMSP-1. Immunogenicity of the recombinant proteins was studied in mice in the absence or presence of different adjuvant formulations. PvMSP-3?, but not PvMSP-3?, induced a TLR4-independent humoral immune response in the absence of any adjuvant formulation. The immunogenicity of the recombinant antigens were also tested in formulations containing different adjuvants (Alum, Salmonella enterica flagellin, CpG, Quil A,TiterMax® and incomplete Freunds adjuvant) and combinations of two adjuvants (Alum plus flagellin, and CpG plus flagellin). Recombinant PvMSP-3? and PvMSP-3? elicited higher antibody titers capable of recognizing P. vivax-infected erythrocytes harvested from malaria patients. Our results confirm that P. vivax MSP-3 antigens are immunogenic during natural infection, and the corresponding recombinant proteins may be useful in elucidating their vaccine potential. © 2013 Bitencourt et al.
Source Title: PLoS ONE
URI: https://scholarbank.nus.edu.sg/handle/10635/166200
ISSN: 19326203
DOI: 10.1371/journal.pone.0056061
Appears in Collections:Staff Publications
Elements

Show full item record
Files in This Item:
File Description SizeFormatAccess SettingsVersion 
10_1371_journal_pone_0056061.pdf1.02 MBAdobe PDF

OPEN

NoneView/Download

SCOPUSTM   
Citations

16
checked on Nov 23, 2020

Page view(s)

47
checked on Nov 20, 2020

Google ScholarTM

Check

Altmetric


Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.